9 February 2023
4basebio plc
(“4basebio” or the "Company")
Exercise of
Options and Issue of Equity
4basebio plc (AIM: 4BB), the specialist life sciences group
focused on exploiting intellectual property in the field of cell
and gene therapies and DNA vaccines, announces that it has received
a notification from an employee to exercise options over 2,000
ordinary shares (“New Ordinary Shares”) in the Company at an
exercise price of 118 pence per share
for total proceeds of £2,360.
Following this exercise of options, the Company has options
outstanding over 710,500 ordinary shares in aggregate, representing
approximately 5.77 per cent. of the Company’s enlarged issued share
capital following admission of the New Ordinary Shares.
Admission to AIM
Application will be made for the New Ordinary Shares to be
admitted to trading on AIM ("Admission"). It is expected that
Admission will become effective at 8.00
a.m. on or around 14 February
2023. The New Ordinary Shares will be issued credited as
fully paid and will rank in full for all dividends and other
distributions declared, made or paid after Admission and will
otherwise rank on Admission pari passu in all respects with the
existing ordinary shares.
Total Voting Rights
Following Admission, the total number of ordinary shares in
issue will be 12,319,473. The Company does not hold any ordinary
shares in treasury. Therefore, the total number of ordinary shares
with voting rights will be 12,319,473. This figure may be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the share capital of
the Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
This announcement contains inside
information for the purposes of Article 7 of EU Regulation
596/2014.
For further information please
contact:
4basebio
plc |
+44 (0)12 2396
7943 |
Heikki Lanckriet, CEO |
|
|
|
Cairn Financial Advisers LLP
(Nominated Adviser) |
+44 (0)20 7213
0880 |
Jo Turner / Sandy Jamieson |
|
|
|
finnCap Ltd (Broker) |
+44 (0)20 7220
0500 |
Geoff Nash/Richard
Chambers/Charlotte Sutcliffe |
|
|
|